Novartis Ag (NVSEF) Research & Development (2009 - 2025)

Novartis Ag has disclosed Research & Development across 15 years of filings, most recently posting -$2.7 billion for Q2 2025.

• Research & Development for Q2 2025 came in at -$2.7 billion, down 15.21% year-over-year; the trailing twelve-month figure through Jun 2025 was -$14.8 billion (down 51.1% YoY), and the FY2025 annual result was $11.2 billion, up 11.75% from the prior year.
• Research & Development came in at -$2.7 billion for Q2 2025 at Novartis Ag, up from -$4.8 billion in the prior quarter.
• In the past five years, Research & Development ranged from a high of -$194.0 million in Q3 2022 to a low of -$4.9 billion in Q4 2023.
• The 5-year median for Research & Development is -$1.3 billion (2021), against an average of -$1.7 billion.
• Across the five-year window, Research & Development climbed 13.39% in 2022 and slumped 2058.85% in 2023, its largest moves.
• Novartis Ag's Research & Development stood at -$240.0 million in 2021, then advanced by 5.83% to -$226.0 million in 2022, then plunged by 2058.85% to -$4.9 billion in 2023, then increased by 1.87% to -$4.8 billion in 2024, then soared by 43.05% to -$2.7 billion in 2025.
• The last three Research & Development figures came in at -$2.7 billion (Q2 2025), -$4.8 billion (Q4 2024), and -$2.4 billion (Q2 2024), per Business Quant data.